Introducing ACT's new enewsletter, Lab Views, which will bring you news specific to the laboratory and its uses in clinical trials including deals, alliances, business developments, people news and events.
Bio-Imaging Technologies Buys Phoenix Data Systems
Bio-Imaging Technologies, a provider of medical image management for the clinical trials industry, acquired Phoenix Data Systems, an EDC and eClinical data solutions provider, the end of last month.
>>MORE
Top 3 Clinical Trial Specimen Shipping Concerns
QuickSTAT, a shipping and logistics company specializing in time and temperature critical transportation for the pharmaceutical and biotech industry, gave LabViews the following insight into shipping lab specimens for clinical trials: 1) Protecting specimen integrity 2) Advisory communications 3) Cost.
>>MORE
eRT, PHT, ICON Partner for Oncology Seminar
Northern and Southern California will play host to eResearch Technology's "Partnering in Oncology: Data to Power Decisions" on May 12 and May 13 in Burlingame and La Jolla, respectively. Topics include Imaging in Oncology Trials; Partnering with a CRO in Oncology Trials; and a panel discussion. Speakers include Kenneth A. Getz, MBA, Senior Research Fellow at the Tufts Center for the Study of Drug Development.
>>MORE
WorldCare Clinical
Work with the imaging CRO that is conducting clinical trials in perfect harmony and benefit from clean datasets delivered quickly and cost effectively.
PACS's Lab Information Management Systems (LIMS)
May 10–12 , 2008
Location | Pittsburgh, PA
CfPIE's Effective Laboratory Safety Management
May 12–13 , 2008
Location | Malvern, PA
CfPIE's Current Good Laboratory Practices
May 12–14 , 2008
Location | Dublin, Ireland
Lorraine Marchand
- Clinilabs' new chief operating office.
Helen Jenkinson
- ACM Pivotal's new UK-based senior clinical laboratory scientist.
Holly Smith
- New director of Profect Medical Technologies' Clinical Imaging Services
Want to peer more into the future of the lab's impact on drug development? This opinion from Tepnel Research Products and Services is about the use of genotyping.
The WSJ Health Blog explores LabCorp's view of genetic diagnostic tests and its importance to the future of drug development.
You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.
To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
2 Commerce Drive
Cranbury, NJ 08512